Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a leading clinical stage immuno-oncology company that is pioneering the development of innovative therapies to treat cancer. The company's research is focused on CD47, a molecule that tumors use to evade the immune system, and aims to block this "do not eat" signal with decoy receptors. By doing so, they hope to unmask tumor cells and make them visible to, and eradicated by, the immune system. Trillium is committed to using the latest scientific advancements to develop new treatments that will help those suffering from cancer.